期刊文献+

腹膜透析相关性腹膜炎患者促红细胞生成素抵抗的原因分析 被引量:1

下载PDF
导出
摘要 选取2012年6月~2013年12月在我中心进行腹膜透析随访的患者共90例。其中正常对照组45例,腹膜炎组45例,比较两组临床及实验室数据差异,分析腹膜透析相关性腹膜炎患者促红细胞生成素(EPO)抵抗的原因。结果两组临床指标无显著差异,基线指标如网织红细胞、血红蛋白、红细胞比积、白蛋白、前白蛋白等无统计学差异,但腹膜炎组促红素抵抗指数(ERI)值较对照组明显增高(P≤0.05),Hb变异度亦明显高于对照组(P≤0.05),腹膜炎组铁蛋白明显高于对照组(P≤0.01),而转铁蛋白饱和度低于对照组(P≤0.05),腹膜炎组较对照组有更高的i PTH值(P≤0.05),更低的总KT/V(P≤0.01)。腹膜透析相关性腹膜炎患者出现明显的促红素抵抗,可能与炎症状态时,铁吸收利用障碍,透析欠充分及更为严重的继发性甲状旁腺功能亢进相关。
出处 《现代诊断与治疗》 CAS 2015年第8期1852-1853,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献4

  • 1KDOQI,National Kidney Foundation.KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for anemia in chronic kidney disease[J].Am J Kidney Dis,2006,47(5 Suppl 3): Sll-S145.
  • 2Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease[J].Kidney Int,2011,80(5):464- 74.
  • 3霍苗苗,林曰勇,余毅.慢性肾脏病促红细胞生成素抵抗研究进展[J].中国中西医结合肾病杂志,2012,13(2):183-185. 被引量:7
  • 4Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD[J].J Am Soe Nephrol,2007,18(12):3164- 3170.

二级参考文献28

  • 1KDOQI,National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for anemia in chronic kidney disease[J].American Journal of Kidney Diseases,2006,(5 Suppl 3):S11-S145.
  • 2Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease[J].Kidney International,2011,(05):464-474.
  • 3Bamgbola OF,Kaskel FJ,Coco M. Analyses of age,gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts[J].Pediatric Nephrology,2009,(03):571-579.doi:10.1007/s00467-008-0954-3.
  • 4Góes MA,Dalboni MA,Manfredi SR. Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease[J].Clinical Nephrology,2010,(01):7-13.
  • 5Betjes MG,Weimar W,Litjens NH. CMV seropositivity determines epoetin dose and hemoglobin levels in patients with CKD[J].Journal of the American Society of Nephrology,2009,(12):2661-2666.
  • 6Johnson-Wimbley TD,Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century[J].Therap Adv Gastroenterol,2011,(03):177-184.
  • 7Foley RN,Curtis BM,Parfrey PS. Erythropoietin therapy,hemoglobin targets,and quality of life in healthy hemodialysis patients:a randomized trial[J].Clin J Am Soc Nephrol,2009,(04):726-733.
  • 8Kapoian T,O'Mara NB,Singh AK. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin[J].Journal of the American Society of Nephrology,2008,(02):372-379.
  • 9Battistella M,Richardson RM,Bargman JM. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease[J].Clinical Nephrology,2011,(02):99-103.
  • 10Brunner S,Theiss HD,Murr A. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells[J].American Journal of Physiology Endocrinology and Metabolism,2007,(16):E1670-E1675.

共引文献6

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部